Prevention & Lipids
GLP-1 RA effects on CV events and mortality
Emerging evidence with 100 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does glucagon-like peptide-1 receptor agonists vs placebo improve outcomes in Diabetes Mellitus, Non-Insulin-Dependent?
Low Certainty+ Favors benefitglucagon-like peptide-1 receptor agonists vs placebo · Cardiovascular Mortality
Does metformin vs placebo improve outcomes in Diabetes Mellitus, Non-Insulin-Dependent?
Low Certainty+ Favors benefitmetformin vs placebo · Myocardial Infarction Hospitalization
Does proton-pump inhibitors vs placebo improve outcomes in Acute Coronary Syndrome?
Low Certainty+ Favors benefitproton-pump inhibitors vs placebo · Cardiac Output
Does semaglutide vs placebo improve outcomes in Diabetes Mellitus, Insulin-Dependent?
Low Certainty+ Favors benefitsemaglutide vs placebo · Cardiac Output
Does insulin, regular, human vs placebo improve outcomes in Obesity?
Low Certainty+ Favors benefitinsulin, regular, human vs placebo · Cardiac Output
Does empagliflozin vs placebo improve outcomes in Diabetes Mellitus, Insulin-Dependent?
Low Certainty+ Favors benefitempagliflozin vs placebo · Cardiac Output
Does dapagliflozin vs isoproterenol improve Myocardial Infarction Hospitalization in Myocardial Infarction?
Low Certainty+ Favors benefitdapagliflozin vs isoproterenol · Myocardial Infarction Hospitalization
Does angiotensin ii vs placebo improve outcomes in Cardiac Hypertrophy?
Low Certainty+ Favors benefitangiotensin ii vs placebo · Myocardial Infarction Hospitalization
Does semaglutide vs placebo improve outcomes in Obesity?
Low Certainty− Favors harmsemaglutide vs placebo · Urinary Tract Infection
Does nitric oxide vs placebo improve outcomes in Hypertension, Pulmonary?
Low Certainty− Favors harmnitric oxide vs placebo · Heart Rate
Does dulaglutide vs placebo improve outcomes in Diabetes Mellitus, Non-Insulin-Dependent?
Low Certainty− Favors harmdulaglutide vs placebo · Heart Rate
Does insulin, regular, human vs placebo improve outcomes in Insulin Resistance?
Low Certainty− Favors harminsulin, regular, human vs placebo · Cardiac Output
GLP-1 agonists cardiovascular outcomes (also known as GLP-1 CV, semaglutide cardiovascular, GLP1 heart). GLP-1 RA effects on CV events and mortality
Synapse tracks 20 specific clinical questions in GLP-1 agonists cardiovascular outcomes, each synthesized independently from its own trial evidence. They include: "Does glucagon-like peptide-1 receptor agonists vs placebo improve outcomes in Diabetes Mellitus, Non-Insulin-Dependent?"; "Does metformin vs placebo improve outcomes in Diabetes Mellitus, Non-Insulin-Dependent?"; "Does proton-pump inhibitors vs placebo improve outcomes in Acute Coronary Syndrome?"; "Does semaglutide vs placebo improve outcomes in Diabetes Mellitus, Insulin-Dependent?"; "Does insulin, regular, human vs placebo improve outcomes in Obesity?".
As of 2026-06-25, the scientific consensus on GLP-1 agonists cardiovascular outcomes is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/69b0a315b42209bc31dca34a.
Deterministic synthesis from Synapse's enriched corpus — 138 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every GLP-1 agonists cardiovascular outcomes paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search GLP-1 agonists cardiovascular outcomes papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers